Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
2.570
-0.060 (-2.28%)
Feb 21, 2025, 4:00 PM EST - Market closed
Geron Employees
Geron had 141 employees as of December 31, 2023. The number of employees increased by 34 or 31.78% compared to the previous year.
Employees
141
Change (1Y)
34
Growth (1Y)
31.78%
Revenue / Employee
$209,078
Profits / Employee
-$1,426,901
Market Cap
1.55B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
GERN News
- 17 hours ago - 3 Biotech/Healthcare Names Under $10 I Am Buying Now - Seeking Alpha
- 1 day ago - Geron to Participate at Upcoming Investor Conferences in March 2025 - Business Wire
- 2 days ago - Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch - Seeking Alpha
- 19 days ago - Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - Business Wire
- 5 weeks ago - Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales - Seeking Alpha
- 2 months ago - Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS - Business Wire
- 2 months ago - Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies - Business Wire